Document is current
Any future updates will be listed below
-
Authors
McMurdie, Paul J. http://orcid.org/0000-0001-8879-3954
Stoeva, Magdalena K. http://orcid.org/0000-0002-6974-6009
Justice, Nicholas http://orcid.org/0000-0003-0124-2119
Nemchek, Madeleine http://orcid.org/0000-0002-8279-4021
Sieber, Christian M. K. http://orcid.org/0000-0002-9560-0281
Tyagi, Surabhi http://orcid.org/0000-0002-1578-6777
Gines, Jessica
Skennerton, Connor T. http://orcid.org/0000-0003-1320-4873
Souza, Michael http://orcid.org/0000-0003-0370-8189
Kolterman, Orville http://orcid.org/0000-0002-9306-1288
Eid, John http://orcid.org/0000-0002-2099-8344
- License Information
-
More Information
Article History
Received: 29 June 2021
Accepted: 7 December 2021
First Online: 8 January 2022
Declarations
:
: The original trial protocol was approved by a central institutional review board (Allendale, Old Lyme, Connecticut, USA), and was conducted in accordance with the Declaration of Helsinki as amended in 2013 and Good Clinical Practice guidelines. Written informed consent was obtained from each subject prior to participation in any trial activities.
: Not applicable.
: All authors are employees and stock/stock option shareholders of Pendulum Therapeutics, Inc. (formerly known as ‘Whole Biome Inc.’). O.K. also owns stock in GlySens, Inc., has stock options in ViaCyte, Inc. and NanoPrecision Medical.
